In the midst of the second wave of the COVID-19 pandemic, AYUSH-64 has emerged as a potential cure for mild and moderate COVID-19 infection.
Ayush 64, a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush is useful in the treatment of asymptomatic, mild and moderate COVID-19 infection as an adjunct to standard care.
The Ministry of Ayush-Council of Scientific and Industrial Research (CSIR) collaboration has recently completed a multi-centre clinical trial to evaluate the safety and efficacy of AYUSH 64 in the management of mild to moderate COVID-19 patients.
AYUSH 64 comprises of Alstonia scholaris (aqueous bark extract), Picrorhiza kurroa (aqueous rhizome extract), Swertia chirata (aqueous extract of whole plant) and Caesalpinia crista (fine-powdered seed pulp). It is extensively studied, scientifically developed, safe and effective Ayurveda formulation. This medicine is also recommended in National Clinical Management Protocol based on Ayurveda and Yoga which is vetted by National Task Force on COVID-19 Management of ICMR.
Dr Arvind Chopra, Director, Centre for Rheumatic Diseases, Pune and honorary chief clinical coordinator of the Ministry of Ayush – CSIR collaboration informed that the trial was conducted at three centres. KGMU, Lucknow; DMIMS, Wardha and BMC COVID Centre, Mumbai involving 70 participants in each arm.
He also shared that several significant beneficial effects of AYUSH 64 on general health, fatigue, anxiety, stress, appetite, general happiness and sleep were also observed.
However, he said that patients on AYUSH 64 will still require monitoring so as to identify any worsening of disease requiring more intensive therapy with oxygen and other treatment measures provided during hospitalization.
Dr. V M Katoch, Chairman of the MC informed that the committee has carefully reviewed the outcome of AYUSH 64 study and recommended AYUSH 64 in the management of asymptomatic, mild to moderate COVID-19.
The committee has also recommended Ministry to communicate to the state licensing authorities/regulators regarding adding new indication of AYUSH 64 for repurposing in the management of mild to moderate COVID-19.
Another doctor, N Srikanth, Director General, CCRAS elaborated that additional studies on Ayush 64 are underway at reputed research institutes, have shown the usefulness of AYUSH 64 in dealing with mild and moderate COVID-19. He also added that the outcome of the seven clinical studies has revealed that AYUSH 64 exhibits early clinical recovery in COVID-19 cases without further progression.